In 2017 the following changes were made to the National Immunisation Schedule.
All children transfer to the new Schedule from 1 January 2017 (HPV changes) and 1 July 2017 (other scheduled vaccine changes), although some new vaccines will not be available until existing stocks are used up. There are no changes to the ages of the routine immunisation events.
Key Changes to the National Immunisation Schedule
From 1 January 2017:
Human papillomavirus vaccine
- Funded access was widened to include males and females aged 9 to 26 years.
- A two-dose regimen was funded for those children aged 14 years and under.
- A three-dose regimen was funded for people aged 15 to 26 years.
- The older quadrivalent HPV vaccine Gardasil was replaced with the 9-valent Gardasil 9.
A range of changes to the Schedule take effect from 1 July 2017, including the addition of varicella vaccine:
|Vaccine||Brand Name||Scheduled Event||Route||New/Replaces|
|1.||Rotavirus vaccine (RV)||Rotarix||6 weeks, 3 months||Oral||Replaces 3 dose regimen of Rotateq at 6 weeks, 3 months and 5 months.|
|2.||10-valent pneumococcal vaccine (PCV10)||Synflorix||6 weeks, 3, 5, & 15 months||IM||Replaces 13-valent pneumococcal conjugate vaccine (PCV13, Prevenar 13) event at 6 weeks, 3, 5, and 15 months^|
|3.||Varicella vaccine (VV)||Varilrix||15 months*||SC||New on schedule|
|4.||MMR (measles, mumps and rubella)||Priorix||15 months, 4 years||SC||Replaces MMR-II|
|5.||Haemophilus influenzae type b (Hib)||Hiberix||15 months||IM||Replaces Act-Hib|
Funding criteria for high-risk patients remain unchanged.
^Prevenar 13 will remain available for high-risk patients only.
*Varicella vaccine is funded for children born on or after 1 April 2016, at their 15 month immunisation event. It is also funded for children who turn age 11 years on or after 1 July 2017 if they have not previously been infected with chickenpox or vaccinated against it.
The Immunisation Advisory Centre has produced a short video explaining the changes.